ACG Wealth’s Iovance Biotherapeutics IOVA Stock Holding History

ACG Wealth’s Portfolio IOVA Stock Details IOVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-200	Closed	-$2K	–	601
2022 Q2	$2K	Buy	+200	New	+$2.62K	﹤0.01%	820

Other funds holding IOVA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

ACG Wealth's IOVA Position: Q3 2022 in Review

ACG Wealth sold out of Iovance Biotherapeutics (IOVA) in Q3 2022, closing a stake of 200 shares — an estimated $2K sold.

ACG Wealth first reported a position in IOVA in Q2 2022 and held it in 1 quarter. The position peaked at $2K in Q2 2022. 242 funds tracked by Wall St. Rank hold IOVA as of Q3 2022.

ACG Wealth reported no remaining Iovance Biotherapeutics position as of Q3 2022 after selling out during the quarter.
ACG Wealth sold 200 Iovance Biotherapeutics shares in Q3 2022, an estimated $2K.
ACG Wealth first reported a position in Iovance Biotherapeutics in Q2 2022 and held it in 1 quarter.
ACG Wealth's Iovance Biotherapeutics position peaked at $2K in Q2 2022.
242 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q3 2022.

Based on ACG Wealth's 13F filing for Q3 2022, filed 3 Nov 2022.